Review: Penggunaan Statin sebagai Obat Off-Label

Ayu Previani Hartono; Sri Adi Sumiwi

doi:10.24198/farmaka.v21i3.46895

Review: Penggunaan Statin sebagai Obat Off-Label

Ayu Previani Hartono, Sri Adi Sumiwi

Abstrak

Penggunaan obat off-label secara luas dikenal sebagai penggunaan obat yang tidak disetujui dari obat yang disetujui. Statin merupakan penghambat enzim hidroksimetilglutaril-CoA (HMG-CoA) yang menurunkan konsentrasi kolesterol total, lipoprotein densitas rendah (LDL), dan meningkatkan konsentrasi lipoprotein densitas tinggi (HDL). Selain itu, statin memiliki efek pleiotropik yang dapat memengaruhi patofisiologi penyakit termasuk modulasi respons imun, peningkatan proses anti-inflamasi, dan perubahan jalur pensinyalan yang melibatkan kolesterol. Oleh karena itu, statin berpotensi menjadi pilihan alternatif lain untuk terapi pada beberapa penyakit seperti hepatocellular carcinoma, rheumatoid arthritis, multiple sclerosis, dan COVID-19. Metode penelitian yang dilakukan adalah dengan meninjau pustaka secara digital dengan rentang waktu 2012-2022.

Teks Lengkap:

PDF

Referensi

Abdalla, M., Zakhary, C., Rushdi, H., Hamdan, J., Youssef, K., Khan, A., & Khan, S. (2021). The Effectiveness of Statins as Potential Therapy for Multiple Sclerosis: A Systematic Review of Randomized Controlled trials. Cureus, 13(9).

Amarenco, P., & Tonkin, A. (2004). Statins for stroke prevention: disappointment and hope. Circulation, 23(Suppl 1), 44-49.

Aronson, J., & Ferner, R. (2017). Unlicensed and off-label uses of medicines: Definitions and clarification of terminology. Br. J.Clin. Pharmacol, 83, 2615-2625.

Balogh, J., Victor, D., Asham, E., Burroughs, S., Boktour, M., Saharia, A., Mounsour, H. (2016). Hepatocelullar carcinoma: a review. J Hepatocell Carcinoma, 3, 41-53.

Banach, M., Serban, C., Sahebkar, A., Mikhailidis, D., Ursoniu, S., Ray, K., & et al. (2015). Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med, 13.

Bruix, J., & Sherman, M. (2010). AASLD Practice Guidelines: management of hepatocellular carcinoma: an update. Hepatology, 1-35.

Cardwell, C., Hicks, B., Hughes, C., & et al. (2014). Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol, 32, 3177-3183.

Chong, L., Hsu, Y., Lee, T., Lin, Y., Chiu, Y., Yang, K., Huang, Y. (2015). Fluvastatin Attenuates Hepatic Steatosis-Induced Fibrogenesis in Rats through Inhibiting Paracrine Effect of Hepatocyte on Hepatic Stellate Cells. BMC Gastroenterology, 15(22), 1-13.

Davies, J., Delfino, S., Feinberg, C., Johnson, M., Nappi, V., Olinger, J., Swanson, H. (2016). Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. Lipid Insights, 9, 13-29.

Dilokthornsakul, P., Valuck, R., Nair, K., Corboy, J., Allen, R., & Campbell, J. (2016). Multiple sclerosis prevalence in the United States commercially insured population. Neurology, 86, 1014-1021.

Fajgenbaum, D., & Rader, D. (2020). Teaching Old Drugs New Tricks: Statins for COVID-19? Cell Metabolism, 145-147.

Federico, A., Orditura, M., Cotticelli, G., & et al. (2015). Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett, 9, 1628-1632.

Forner, A., Reig, M., & Bruix, J. (2018). Hepatocelullar carcinoma. Lancet, 391, 1301-1314.

Golocorbin-Kon, S., Ilickovic, I., & Mikov, M. (2015). Reasons for and frequency of off-label drug use. Med. Pregl., 68, 35-40.

Grundy, S., Stone, N., Bailey, A., Beam, C., Birtcher, K., Blumenthal, R., et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25), e1082-e1143.

Hansildaar, R., Vedder, D., Baniaamam, M., Tausche, A., Gerritsen, M., & Numohamed, M. (2021). Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet, 3(1), 58-70.

Henriksbo, B., Lau, T., Cavallari, J., Denou, E., Chi, W., Lally, J., Fullerton, M. (2014). Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes, 3742-3747.

Higashi, T., Friedman, S., & Hoshida, Y. (2017). Hepatic State Cells as Key Target in Liver Fibrosis. Adv. Drug Deliv. Rev, 121, 27-42.

Islam, M., Poly, T., Walther, B., Yang, H., & Li, Y. (2020). Statin Use and the Risk of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. Cancers (Basel), 12(3), 671.

Jiang, W., Hu, J., He, X., Jin, W., & He, X. (2021). Statins: a repurposed drug to fight cancer. J Exp Clin Cancer, 40.

Joyce, A., & Dennis, J. (2015). Simvastatin: Multiple Sclerosis. Hosp Pharm, 50(6), 464-466.

Koopal, C., Marais, A., & Visseren, F. (2017). Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. Curr Opin Endocrinol Diabetes Obes, 24(2), 133-139.

Lenk, C., & Duttge, G. (2014). Ethical and legal framework and regulation for off-label use: European perspective. Ther. Clin. Risk Manag., 10, 537-546.

Liao, K., Playford, M., Frits, M., Coblyn, J., Iannaccone, C., Weinblatt, M., & et al. (2015). The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc, 4, 1-8.

Luirink, I., Wiegman, A., Kusters, D., Hof, M., Groothoff, J., de Groot, E., Hutten, B. (2019). 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med, 381(16), 1547-1556.

McGowan, M., Hosseini, D., Moriarty, P., & Duell, P. (2019). Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. J Am Heart Assoc, 8(24), e13225.

Minder, C., Blumenthal, R., & Blaha, M. (2013). Statins for primary prevention of cardiovascular disease. Curr Opin Cardiol, 28, 554-560.

O'Malley, P., Arnold, M., Kelley, C., Spacek, L., Buelt, A., Natarajan, S., Downs, J. (2020). Management of Dyslipidemia for Cardiovaskular Disease Risk Reduction. Ann Intern Med, 173(10), 822-829.

Pertzov, B., Eliakim-Raz, N., Atamna, H., Trestioreanu, A., Yahav, D., & Leibovici, L. (2019). Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults - A systematic review and meta-analysis. Clin. Microbiol. Infect, 25, 280-289.

Reiner, Z., Hatamipour, M., Banach, M., Pirro, M., Al-Rasadi, K., Jamialahmadi, T., Sahebkar, A. (2020). Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch. Med. Sci., 16, 490-496.

Rezaie-Majd, A., Maca, T., Bucek, R., Valent, P., Muller, M., Husslein, P., Baghestanian, M. (2002). Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol., 22, 1194-1199.

Rusz, C.-M., Osz, B.-E., Jitca, G., Miklos, A., Batrinu, M.-G., & Imre, S. (2021). Off-Label Medication: From a Simple Concept to Complex Practical Aspects. Int J Environ Res Public Health, 18(19), 10447.

Rygiel, K. (2018). Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies. Curr Cardiol Rev, 14(1), 67-76.

Shin, Y., Min, J., Lee, E., Kim, G., Kim, M., Lee, J., & Ahn, H. (2017). The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts. Heart Vessels, 618-627.

Soulaidopoulos, S., Nikiphorou, E., Dimitroulas, T., & Kitas, G. (2018). The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis. Front Med (Lausanne), 5, 24.

Strilchuk, L., Tocci, G., Fogacci, F., & Cicero, A. (2020). An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opin Pharmacother, 21(5), 531-539.

Thrift, A., Natarajan, Y., Liu, Y., & El-Serag, H. (2019). Statin use after diagnosis of hepatocellular carcinoma and patient survival: findings from a retrospective cohort study. Clin Gastroenterol Hepatol, 17(10), 2117-2125.

van Rosendael, A., van den Hoogen, I., Gianni, U., Ma, X., Tantawy, S., Bax, A., et al. (2021). Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition. JAMA Cardiol, 6(11), 1257-1266.

DOI: https://doi.org/10.24198/farmaka.v21i3.46895

DOI (PDF): https://doi.org/10.24198/farmaka.v21i3.46895.g21457